About us



Van Leeuwenhoeck Research (VLR) is an independent research company, enabling institutional investors and other professional investors to better understand the real value of innovative Life Sciences companies they invest in. VLR can tap into a selected circle of top analysts in L...

Published by: Marcel Wijma | Date: 29 August 2010

Van Leeuwenhoeck Research, Inc. (VLR) announced that it has launched a new monthly magazine called LS Tribune. The new publication, edited by Founder and Chief Executive Officer Marcel Wijma, will detail news and developments in the global biotech and pharmaceutical industries.

Published by: Marcel Wijma | Date: 24 July 2010

Dutch/Danish biotech company Genmab saw a strong rebound in its share price of more than 50% from a low of DKK 40. The primary reason for this in our opinion was due to the outcome of a renegotiated partnership with GSK on Arzerra. This provides Genmab with a upfront payment of STG 90 million. The payment is inclusive of the reduced R&D expenses for Genmab on Arzerra, giving Genmab much needed financial stability and also the first sign towards earning back its investors trust. More to follow.



Exelixis Reports Inducement Gr...

Date: 04 September 2010

[Business Wire] - SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new e...

Curis to Present at the Rodman...

Date: 03 September 2010

[Business Wire] - CAMBRIDGE, Mass.----Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the...